CELCCelcuity Inc.
Services-Medical Laboratories
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$172M
- 52% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$182M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$28M | −$39M | −$66M | −$113M | −$172M | 52% |
| Net income | −$30M | −$40M | −$64M | −$112M | −$177M | 58% |
| Operating cash flow | −$20M | −$36M | −$54M | −$83M | −$153M | 84% |
| Capex | $82K | $159K | $98K | $250K | $249K | 0.4% |
| Stock-based comp | $3M | $5M | $5M | $7M | $21M | 206% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.